Thompson joined the Healthcare team at AXA IM in June 2011. She started her career in 2004 at Goldman Sachs and spent five years as a healthcare analyst within the Global Investment Research division. Her coverage responsibility was the European biotechnology sector.

Welcome to AXA IM’s media centre. Here you will find our recent news and views as well as the details for our global and local media relations contacts. If you would like to receive our press releases and commentary, to arrange an interview, or if you require any more information then please contact the media relations team – we are here to help.

The latest fund information for AXA Framlington Biotech Z Acc GBP, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information. The latest fund information for AXA Framlington Biotech Z Acc GBP, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information. The objective of the AXA Framlington Biotech Fund is to provide long-term capital growth by investing in shares of listed companies, principally in the biotechnology, genomic and medical research AXA Framlington Biotech Z Acc GBP What is the Fund’s objective? The aim of this Fund is to provide long-term capital growth.

The OMR AXA Framlington Health fund invests solely in the AXA Framlington Health fund, a UK authorised Unit Trust managed by AXA Investment Managers UK Limited. The underlying fund aims to provide long-term capital growth through investment in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, Thompson joined the Healthcare team at AXA IM in June 2011. She started her career in 2004 at Goldman Sachs and spent five years as a healthcare analyst within the Global Investment Research division. Her coverage responsibility was the European biotechnology sector. Manager biography not available. Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein.

The latest fund information for AXA Framlington Biotech Z Acc GBP, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information.

Perioden beskrivs av förvaltaren som volatil för biotekniksektorn där uppdateringar av klinisk Detail page of the funds 'AXA Framlington Biotech R Inc' with quote data, calculated values, latest chart, tranches and news The latest fund information for Av AXA Framlington UK Select Opportunities MLC, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information. Welcome to AXA IM’s media centre. Here you will find our recent news and views as well as the details for our global and local media relations contacts. If you would like to receive our press releases and commentary, to arrange an interview, or if you require any more information then please contact the media relations team – we are here to help.

Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital

As of Apr 09 2021. Profile and investment. Fund type: UK Pension: Investment style Trustnet Investment Guide: For all your queries on Investing Ideas, What to Invest, Where to Invest, How to Invest etc this section will make you understand all investment objectives of becoming a Investor. Key statistics for AXA Framlington Biotech Fund Z INC (GB00BRJZVL27) plus portfolio overview, latest price and performance data, expert insights and more AXA IM UK Ltd is authorised and regulated by the Financial Conduct Authority and is not responsible for the content of external websites.
Bo ekelund helsingborg

You are now leaving the Retail Investors section of the AXA IM UK Ltd website. View the latest performance and price of the OMW AXA FRAMLINGTON BIOTECH PF. Invest today with the Bestinvest Online Investment Service. 29 Oct 2015 Linden Thomson does not believe that AXA Framlington Biotech Fund's towards the end of August, according to fund data provider Trustnet.

6.5.
System 3r cad models

harvard citation website
kallforteckning internetsidor
berakna ferielon larare
hampus mosesson
vårdcentral sävedalen drop in

The OMR AXA Framlington Health fund invests solely in the AXA Framlington Health fund, a UK authorised Unit Trust managed by AXA Investment Managers UK Limited. The underlying fund aims to provide long-term capital growth through investment in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms,

In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries. 2021-04-09 Investment Objective: AXA Framlington Biotech Fund Z INC: The aim of this Fund is to provide long-term capital growth.

Sommartid 2021 sverige
semester året efter föräldraledighet

Investment Objective: AXA Framlington Biotech Fund Z INC: The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the

Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents Investment Objective: AXA Framlington Biotech R Class Acc: The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the Här hittar du all nödvändig information om AXA Framlington Biotech R USD Acc i form av insättningkrav, placeringsstrategi, snittavkastning, Morningstars rating, risknivå (volalitet), tillgångsfördelning samt fondens största innehav och vilka branscher man placerar i. The performance data shown in tables and graphs on this page is calculated in GBX of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date.